Enlivex Therapeutics Ltd. [NASDAQ: ENLV] has revealed that it has decided to close the earlier declared offering of 2,296,107 ordinary shares, par value NIS 0.40 per share, of the firm at a price to the public of $20.00 per common share, subtracting the underwriting deductions and expenses.
The representative of the firm for this offering is H.C. Wainwright & Co. Enlivex Therapeutics has also provided the 30-day option to the underwriters for the buying of 344,416 additional common shares at the public offering price, subtracting underwriting concessions and fees.
Shares of Enlivex Therapeutics [NASDAQ: ENLV] went down 5.17% at $20.00 during the trading session of Friday. It has recorded a trading volume of 809.57K as compared to the average volume of 458.54K. Enlivex share went down 457.10% during the past 52-week low and went up -31.97% during the past 52-week high. This company has a total market capitalization of $219.60 million at the time of writing.
Enlivex stated that the gains from the contribution before subtracting the underwriting concessions and charges are nearly $45.92 million. The firm is planning to use the profit from the contribution for the three main goals.
The first plan of the firm is to use the profit for medical, regulatory, production and study and improvement movements, the second plan of the firm is to use the profit for possible buying and in-licensing, and the third plan of the firm is to use it for other objectives of the firm.